Sara A. Hurvitz, MD, Discusses Outcomes With Sacituzumab Govitecan By Age for Metastatic Triple-Negative Breast Cancer

Video

CancerNetwork® sat down with Sara A. Hurvitz, MD, at the 2021 ASCO Annual Meeting to talk about multidisciplinary care with geriatrician oncologists and the use of age-based analyses for diagnosis and following up of metastatic triple-negative breast cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Sara A. Hurvitz, MD, from the University of California, Los Angeles Jonsson Comprehensive Cancer Center, about utilizing sacituzumab govitecan (Trodelvy) for the treatment of older patients with metastatic triple-negative breast cancer (mTNBC).

Sacituzumab govitecan was examined in the phase 3 ASCENT study (NCT02574455) in patients with relapsed/refractory TNBC with subgroup analyses performed to assess the impact of age. The study found that regardless of age (≥65 or <65 years), patients who had received 2 or more chemotherapies had a significant survival benefit with use of sacituzumab govitecan.

Transcript:

It’s quite important for us as clinical investigators to explore outcomes based on age. We do have an aging population and cancer is a disease that, at least in breast cancer, increases [with patients who are] increasing in age. It is really important for us to look at outcomes based on age. From a geriatrician standpoint, I think they would support this type of analysis because treatment decisions across the board—whether it’s in cardiology, pulmonology, oncology, or endocrinology—should be based on a patient’s performance status and ability to accept therapy rather than a numerical age. I’m reassured that these data show a similar efficacy outcome with the use of sacituzumab as well as a reasonable safety profile. The data will make us all more comfortable offering this therapy that’s associated with a survival benefit to patients, regardless of their age. I’m sure geriatric oncologists applaud this type of analysis.

Reference:

Kalinsky K, Oliveira M, Traina T, et al. Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of Sacituzumab govitecan (SG) in metastatic triple negative breast cancer (mTNBC). J Clin Oncol. 2021;39(suppl 15):1011. doi: 10.1200/JCO.2021.39.15_suppl.1011

Related Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content